PX1 Research supplies USA-manufactured Selank 10mg reference standards engineered specifically for in vitro and preclinical laboratory research. Every production lot undergoes rigorous third-party verification, including reverse-phase HPLC purity testing, mass spectrometry sequence validation, and quantitative endotoxin screening. Laboratory investigators can review lot-specific Certificates of Analysis before acquisition to ensure exact experimental reproducibility.
PX1 Research supplies USA-manufactured Selank 10mg reference standards engineered specifically for in vitro and preclinical laboratory research. Every production lot undergoes rigorous third-party verification, including reverse-phase HPLC purity testing, mass spectrometry sequence validation, and quantitative endotoxin screening. Laboratory investigators can review lot-specific Certificates of Analysis before acquisition to ensure exact experimental reproducibility.
To buy Selank 10mg research standards with verified analytical purity, principal investigators require transparent documentation, lot-specific testing, and certified domestic manufacturing. PX1 Research delivers lyophilized 10mg Selank vials featuring >98% purity confirmed via HPLC and ESI-MS, sterile vial packaging, and quantitative endotoxin limits under 0.01 EU/mg to safeguard sensitive cell culture and tissue assays.
Acquiring high-purity reference peptides for controlled laboratory experimentation demands absolute confidence in compound identity and stability. Inferior or unverified neuropeptide preparations introduce critical confounding variables in neurochemical, gene expression, and binding assays. By establishing strict quality thresholds across every step of synthesis, purification, and lyophilization, PX1 Research provides academic, biotechnology, and institutional laboratories with the standardized materials required for reproducible, high-impact data generation.
Selank is a synthetic regulatory heptapeptide derived from the sequence of the naturally occurring tetrapeptide tuftsin (Thr-Lys-Pro-Arg), an endogenous immunomodulatory peptide produced in the spleen. To extend the metabolic half-life and enhance resistance to serum peptidases, synthetic chemists modified the native tuftsin sequence by attaching a C-terminal tripeptide proline-glycine-proline (Pro-Gly-Pro) motif. The resulting heptapeptide sequence—Thr-Lys-Pro-Arg-Pro-Gly-Pro—demonstrates substantially altered enzymatic stability relative to its precursor.
In preclinical structural analyses, the addition of the Pro-Gly-Pro sequence stabilizes the peptide backbone against rapid degradation by serum carboxypeptidases and aminopeptidases. This chemical modification allows researchers studying tuftsin analog studies to investigate sustained receptor dynamics and downstream signaling cascades without the confounding rapid breakdown observed in unmodified native oligopeptides. Investigating these structural variations provides essential insights into metabolic stabilization strategies within modern peptide design.
Preclinical investigations indicate that Selank interacts directly and indirectly with gamma-aminobutyric acid (GABA) neurotransmitter systems. In vitro radioperfusion assays and electrophysiological models demonstrate that while Selank does not bind directly to the orthosteric GABA binding site on the GABA-A receptor, it modulates receptor affinity and allosteric kinetics. Researchers examining rodent cortical membranes have observed altered binding characteristics for GABA ligands following exposure to nanomolar concentrations of Selank.
Furthermore, transcriptomic profiling in preclinical rodent models suggests that Selank administration influences the expression of specific subunit genes encoding the GABA-A receptor complex. Specifically, mRNA expression levels for Gabra1 and Gabra6 subunits demonstrate measurable modulation in response to treatment. These data suggest that Selank acts as a subtle modulatory peptide rather than a classic direct agonist or antagonist, providing a novel framework for exploring non-sedating GABAergic regulation in cellular signaling models.
Beyond GABAergic pathways, preclinical studies suggest that Selank alters serotonergic metabolism and monoamine dynamics within specific brain structures. In vitro tissue assays and in vivo microdialysis models involving rodents reveal transient elevations in 5-hydroxyindoleacetic acid (5-HIAA)—the primary metabolite of serotonin—in the hippocampus and prefrontal cortex following exposure to the peptide. This shift in metabolic turnover points toward altered 5-HT transporter activity or altered enzymatic processing via monoamine oxidase pathways.
Parallel preclinical investigations demonstrate that Selank influences the gene expression of Brain-Derived Neurotrophic Factor (BDNF) and its primary receptor, tropomyosin receptor kinase B (TrkB). Quantitative PCR analyses performed on isolated neural cell cultures show upregulated BDNF mRNA expression within 24 hours of exposure. These findings make Selank a valuable compound for exploring neuroplasticity, dendritic branching, and neuroprotective signaling cascades in controlled neurobiological models.
Because Selank incorporates the structural core of tuftsin, researchers actively explore its peripheral and central immunomodulatory properties. Preclinical data indicate that Selank modulates cytokine gene expression, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), in isolated murine splenocyte and astrocyte cultures. By stabilizing immune signaling without inducing systemic inflammatory responses, the compound serves as an ideal reference model for neuroimmune interaction research.
Cellular assays further highlight Selank's capacity to alter natural killer (NK) cell cytotoxicity and neutrophil activity in vitro. When added to cell cultures subjected to oxidative stress or lipopolysaccharide (LPS) challenge, Selank exposure correlates with a regulated shift in anti-inflammatory cytokine output. This dual action—bridging central neurochemical signaling and peripheral immune regulation—distinguishes Selank from conventional monoaminergic or GABAergic reference agents available across all research peptides.
When designing neuropeptide signaling protocols, researchers frequently compare Selank against other synthetic regulatory peptides derived from endogenous signaling molecules. For example, Semax 10mg is an ACTH(4-10) analog primarily evaluated for melanocortin receptor interactions and neurotrophic factor elevation, whereas Selank acts primarily through GABAergic, serotonergic, and tuftsin-mediated immunomodulatory pathways. Comparing both peptides allows laboratories to differentiate between stress-axis modulation and central inhibitory tuning.
Additionally, broader classes of peptidomimetic neuro-regulators like Noopept or structural tuftsin fragments exhibit markedly different pharmacokinetics and receptor cross-reactivity. While structural tuftsin fragments focus heavily on phagocytic activation and macrophage recruitment, Selank's C-terminal Pro-Gly-Pro tail prioritizes central nervous system metabolic stability. The table below outlines key structural and target differences across these common research reference compounds:
To ensure high experimental precision when investigators place a Selank 10mg buy order, PX1 Research subjects every batch to a comprehensive analytical workflow. Purity is validated using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) with UV detection at 214 nm and 220 nm. This process verifies that total peptide purity exceeds 98%, confirming the absence of truncated synthesis sequences, deletion peptides, or residual protecting groups.
Molecular identity is simultaneously verified using Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF), confirming the exact theoretical mass of the 7-amino-acid chain (751.9 g/mol). Furthermore, because bacterial endotoxins interfere with neural cell culture viability and cytokine assays, PX1 Research conducts quantitative Chromogenic LAL testing on every lot, verifying endotoxin levels remain strictly under 0.01 EU/mg. Investigators can access these data instantly via our PX1 Research analytical portal.
Selank 10mg is supplied as a sterile, lyophilized cake in sealed borosilicate glass vials. Upon receipt, lyophilized vials must be stored in a temperature-controlled freezer at -20°C or -80°C for long-term stability. Lyophilized peptides preserved under deep-freeze conditions remain stable for up to 24 months, provided they are shielded from light and ambient moisture exposure.
Reconstitution should take place within a certified laminar flow hood using sterile laboratory diluents, such as 0.9% Bacteriostatic Sodium Chloride or Sterile Bacteriostatic Water for Injection. For sensitive cell culture applications where benzyl alcohol preservative might confound cellular responses, plain Sterile Water for Injection (WFI) or phosphate-buffered saline (PBS, pH 7.4) should be selected. Detailed liquid handling and molar concentration math can be reviewed in our bacteriostatic water reconstitution protocols. Once reconstituted, liquid aliquots should be kept at 2°C to 8°C and evaluated within 30 days.
Procuring research compounds from unverified foreign sources exposes laboratories to batch-to-batch variability, missing analytical documentation, heavy metal contamination, and degraded peptide chains. PX1 Research eliminates these experimental risks by maintaining strict domestic supply chain control. All synthesis, purification, and lyophilization steps occur within cGMP-compliant, ISO 9001/ISO 17025 certified production facilities located in the United States.
Every production lot is assigned a unique tracking number linked directly to its HPLC chromatogram, mass spectrometry readout, and endotoxin report. Laboratories establishing bulk laboratory accounts benefit from lot-reservation options, ensuring that long-term longitudinal studies utilize the exact same synthesis batch across multi-year experimental timelines. Orders ship directly from our fulfillment centers in California and Arizona, with same-day dispatch for orders finalized prior to cutoff times.
When designing in vitro or ex vivo assays involving Selank 10mg, researchers must carefully control environmental variables that impact peptide stability. Neuropeptides containing proline-rich sequences can exhibit conformational flexibility depending on solvent ionic strength, pH, and divalent cation concentration. Standard cell culture media should be buffered properly to prevent unintended degradation by ambient extracellular peptidases.
Researchers performing binding assays or gene expression profiling are advised to establish negative control vehicles alongside active compound concentrations ranging from 1 nM to 10 µM. Monitoring baseline gene expression before and after peptide exposure yields precise quantitative metrics regarding transcriptomic shifts. For protocols requiring detailed methodological support or comprehensive analytical validation, explore our complete library of endotoxin assay validation guides and HPLC purity verification summaries.
What is Selank 10mg and what is its molecular structure?
Selank 10mg is a synthetic heptapeptide reference standard with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (molecular weight: 751.9 g/mol). It is a modified analog of the naturally occurring immunomodulatory peptide tuftsin, engineered with a C-terminal Pro-Gly-Pro extension for enhanced metabolic stability in laboratory research applications.
What primary research areas involve Selank in preclinical literature?
Preclinical literature investigates Selank primarily across neurochemical and immunomodulatory pathways. Key areas of focus include GABAergic allosteric modulation, serotonergic metabolism, BDNF neurotrophic expression, and cytokine regulation (such as IL-6 and TNF-alpha) in cellular and animal models.
How is the purity of PX1 Research Selank 10mg verified?
Every lot of PX1 Research Selank 10mg is evaluated using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm peptide purity ≥98%, Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular identity, and a Chromogenic LAL assay to guarantee endotoxin levels remain below 0.01 EU/mg.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are synthesized, purified, lyophilized, and quality-tested in cGMP-compliant, ISO-certified facilities in the United States. Orders ship directly from fulfillment facilities in California and Arizona, offering same-day dispatch Monday through Friday.
How should Selank 10mg be stored upon arrival at the laboratory?
Lyophilized Selank 10mg vials should be stored at -20°C or -80°C upon receipt to maintain long-term peptide integrity. Shield vials from light and atmospheric moisture. Following reconstitution with an appropriate sterile diluent, solution aliquots should be stored at 2°C to 8°C for short-term experimental use.
What reconstituted diluents are recommended for laboratory assays?
For routine analytical or biochemical assays, Sterile Bacteriostatic Water (0.9% benzyl alcohol) or 0.9% Sodium Chloride is commonly utilized. For sensitive cell culture or enzymatic assays sensitive to preservatives, Sterile Water for Injection (WFI) or phosphate-buffered saline (PBS, pH 7.4) is recommended.
How does Selank differ structurally and functionally from Semax?
Selank is derived from the immunomodulatory tetrapeptide tuftsin and primarily targets GABAergic, serotonergic, and cytokine expression pathways. Semax is derived from an ACTH(4-10) sequence and acts primarily through melanocortin receptors and neurotrophic factor elevation.
Can academic institutions establish bulk procurement accounts for Selank 10mg?
Yes. Institutional accounts, academic laboratories, and qualified corporate research facilities can request dedicated lot reservation and volume pricing by visiting the PX1 Research wholesale portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.